At a glance
ClinicalIndex Comparison RecordN/ACompleted· 19 enrolled
Drug / intervention
Disulfiramdrug
Likely dose
Disulfiram 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-institutional Translational Clinical Trial of Disulfiram in Men With Recurrent Prostate Cancer as Evident by a Rising PSA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted May 7, 2010·Updated Jun 12, 2018
In Brief
A clinical study evaluating Disulfiram for Prostate Cancer. Completed, enrolled 19 participants across 3 sites.
Detailed Summary
disulfiram is a DNA methyltransferase inhibitor that may provide benefit for patients with prostate cancer by restoring tumor suppressor genes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionJun 2012
TodayJul 2026
First PostedMay 7, 2010
Enrollment StartMay 1, 2010
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.2 years ago
Interventions
Disulfiramdrug
Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days